← Leaderboards
Beata Jastrzebska
Case Western Reserve University
$3,650,725
Attributed
$3,650,725
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $466.9K · FY2016–25$500K$375K$250K$125K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,650,725 · 2
By mechanism
R01$3,650,725 · 2
Top collaborators
No co-investigators on record.
Most similar at Case Western Reserve University
Same institution · by research overlap
- Johannes Friedrich Von Lintig$10,787,916
- Marcin Bernard Golczak$5,422,975
- Paul S Park$7,385,674
- Sanjay Gupta$6,255,407
- Yoshikazu Imanishi$6,876,233
Others in their field
Top investigators on “Opsin”
- Krzysztof Palczewski · University Of California-Irvine$28,174,653
- Karl Alexander Deisseroth · Stanford University$16,434,746
- Craig Montell · University Of California Santa Barbara$14,186,566
- Gabriel H Travis · University Of California Los Angeles$9,538,828
- Edward N Pugh · University Of Pennsylvania$9,472,787
- Jack L. Feldman · University Of California Los Angeles$9,376,705
Research focus
OpsinNovel TherapeuticsMass Spectrum AnalysisLightMembraneNatural RegenerationChromophoreGeneticImpairmentIn VitroMediatingAnimalsApoproteinsMouse Model11 Cis RetinalCellsComplexCombatBindingBinding SitesBiochemicalAnalogBlindnessPhotoreceptors
Grant awards (9)
Novel neuroprotective activities of flavonoids against retinal degenerative diseases$466,900
R01 · FY2025 · EY · contact PI
Novel neuroprotective activities of flavonoids against retinal degenerative diseases$466,900
R01 · FY2024 · EY · contact PI
Novel neuroprotective activities of flavonoids against retinal degenerative diseases$466,900
R01 · FY2023 · EY · contact PI
Novel neuroprotective activities of flavonoids against retinal degenerative diseases$466,900
R01 · FY2022 · EY · contact PI
Non-hydrolysable analogs of retinal chromophore; potential new therapeutics to prevent retinal degeneration$356,625
R01 · FY2020 · EY · contact PI
Non-hydrolysable analogs of retinal chromophore; potential new therapeutics to prevent retinal degeneration$356,625
R01 · FY2019 · EY · contact PI
Non-hydrolysable analogs of retinal chromophore; potential new therapeutics to prevent retinal degeneration$356,625
R01 · FY2018 · EY · contact PI
Non-hydrolysable analogs of retinal chromophore; potential new therapeutics to prevent retinal degeneration$356,625
R01 · FY2017 · EY · contact PI
Non-hydrolysable analogs of retinal chromophore; potential new therapeutics to prevent retinal degeneration$356,625
R01 · FY2016 · EY · contact PI